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INTRODUCTION 
Inflammatory Bowel Diseases (IBD) are intestinal chronic relapsing diseases 
which ethiopathogenesis remains uncertain. The two main forms are ulcerative 
colitis and Crohn’s disease (1-3). 
Several factors have been involved such as genetic susceptibility, environmental 
factors such as smoke, diet, sex, immunological factors as well as the 
microbioma. 
Several treatments are available for IBD but none of them satisfy several criteria 
at the same time such as safety, long-term remission, histopatological healing, 
and specificity.  
We have investigated two different approaches to the treatment of IBD which 
could lead to new drugs development and new treatment algorithm. 
The first part of this thesis is focused on the understanding of the potential role of 
functional food and nutraceuticals in the treatment of IBD. To do so, we 
investigated the role of Curcuma longa in the treatment of chemical induced 
colitis in mice model. Since Curcma Longa has been investigated for is 
antinflammatory role related to the TNFα pathway as well investigators have 
reported few cases of patients with ulcerative colites treated with this herbs, we 
harbored the hypothesis of a role of Curcuma Longa in the treatment f IBD as 
well as we decided to assess its role in intestinal motility. 
The second part of this thesis is based on an immunological approach to develop 
new drugs to induce suppression in Crohn’s disease or to induce mucosa 
immunity such as in colonrectal tumor. The main idea behind this approach is 
that we could manipulate relevant cell-cell interactions using synthetic peptides. 
We demonstrated the role of the unique interaction between molecules 
expressed on intestinal epithelial cells such as CD1d and CEACAM5 and on 
CD8+ T cells. In normal condition this interaction has a relevant role for the 
expansion of the suppressor CD8+ T cells. Here, we characterized this 
interaction, we defined which are the epitope involved in the binding and we 
attempted to develop synthetic peptides from the N domain of CEACAM5 in 
order to manipulate it. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Functional Food and Nutraceuticals in the treatment of Inflammatory 
Bowel Disease 
 
1.1  Background 
Alternative drug treatment is increasing in developed countries. In 
undeveloped countries such as India (70%), Ruwanda (70%), Uganda (60%), 
Tanzania (60%), Benin (80%) and Etiopia (90%) the percentages are high.  
 
 
 
Figure 1. Undeveloped countries 
 
In developed countries such as Belgium (31%), USA (42%), Australia (48%), 
France (49%), Canada (70%), a significant percentage has used alternative 
medicine once in their life. 
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Figure 2. Developed countries 
 
The use of nutraceutical supplements by patients with gastrointestinal disorders 
is growing worldwide.  The literature has shown that there are a discrete number 
of clinical trials that have demonstrated the efficacy of nutraceutical supplements 
for IBD such as Probiotics, prebiotics, Curcuma longa, Boswellia serrata, and fish 
oils. 
The main idea behind the use of nutraceuticals in IBD is the characteristics of 
these products. Several groups have shown their role in modulating inflammatory 
mediators involved in the inflammatory process, altering luminal bacteria, 
modifying the immune response, and rejuvenation of intestinal healing. 
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1.2  Curcuma Longa  
Curcuma Longa (tumeric) is a perennial herb, cultivated in the Southeast Asia. 
Tumeric chemicals include curcumin, demethoxycurcumin, and 
bisdmeethoxycurcumin, as well as volatile oils, sugars, proteins, and resins 
curcumin being the most studied compounds. Different groups have revealed   
that curcumin has a wide range of beneficial properties including anti-
inflammatory activity, antioxidant, chemotherapeutic and chemopreventive, 
antimicrobial (4-20). It has been shown that turmeric also possesses a 
pronounced AchE activity-inhibitory. These studies have paved the way for 
human clinical trials. Due to its long history as a drug, and because patients 
show a preference for natural remedies and for their excellent safety profile 
shown so far, there is, therefore, a discrete number of researchers interested in 
the use of curcumin for therapeutic purposes. 
Its anti-inflammatory and antioxidant effects have been shown in cancer, 
cardiovascular disease as well as diabetes, atherosclerosis, oxidation of LDL, 
myocardial infarction and IBD. It has been reported that it inhibits the following 
biochemical mechanisms: Activating protein-1 (AP-1), Nuclear factor-kappa B 
(NF-kB), 1.2-cyclooxygenase (COX1 and COX2) and lipoxygenase (LOX), TNF-α 
(tumor necrosis factor α), IFN-γ (interferon-γ) and other such as Profiles of 
adhesion molecules and chemokines, INOS (inducible nitric oxide synthase), 
Oxidation of glutathione (GSH). 
The anti-inflammatory activity may be due to the action of the peroxide radicals 
scavenging developed by xanthine and xanthine oxidase. In fact, the anti-
inflammatory effect of turmeric has been demonstrated both on edema induced 
by carrageenan in the rat paw (acute inflammation), both in models of chronic 
inflammation. Turmeric has the ability to inhibit the peroxidation of lipids liposome 
and the damage on DNA induced by peroxide; at low concentrations, also was 
effective in protecting the hepatocytes of the rat by the lipid peroxidation induced 
by paracetamol. Other studies confirm the antioxidant properties through 
modulation of glutathione levels. 
One of the most important activities for IBD derives from the effect of curcumin 
on the TNFα pathway. Curcumin blocks the activation of NF-kB. Different studies 
have focused the attention on the role of Curcumin administration in the 
prevention of the development of colitis in experimental mice model. It has been 
shown that it prevents the Trinitrobenzene Sulfonic Acid (TNBS)-induced colitis 
inhibiting AP-1, Kinase C and NF-kB and the colitis in chemical induced Dextran 
Sodium Sulphate (DSS) model.  
Dendritic cells represent a target of Curcumin since blocking of MAPKs and NF-
kB activation has been described. 
Curcumin has also been shown able to block significantly the proliferation of 
spleen lymphocytes induced interleukin 2 and irreversibly inhibit the expression / 
production of interleukin 2 and interferon-γ by splenic lymphocytes and peritoneal 
macrophages. 
Curcuma longa has potential anticancer remedies. It inhibits the development 
and progression of the tumor (Hatcher, 2008) (Figure 3). 
  
 
 
Figure 3. Stages of tumor progression inhibited by turmeric. 
 
Curcuma inhibits the stage of initiation of cancer by preventing activation of the 
carcinogen and inhibits the proliferation of malignant cells during promotion and 
progression. Several studies have demonstrated the ability of curcumin to reduce 
the incidence of tumors induced by benzo (a) pyrene and 7.12 dimethyl benz (a) 
anthracene and the tumor promoting phorbol ester-induced mouse skin.  
Other studies have shown that curcumin inhibits the development of stomach 
cancer induced by N-methyl-N-nitro-N-nitrosoguanina (MNNG); in rats reduces 
the incidence and / or the multiplicity of esophageal tumors and preneoplastic 
lesions induced from N-nitrosometilbenzilammina. The diet of turmeric has 
significantly reduced the azoximetano-induced preneoplastic lesions in the 
incidence and / or the multiplicity of tumors at the level of the colon. 
Curcumin seems to act simultaneously inhibiting angiogenesis, inducing 
apoptosis, or more generally the cell death, and acting directly and indirectly 
(metabolism carcinogens) on carcinogens. 
 
1.3 Curcuma and IBD 
Several group have studied the role of curcuma in experimental mice model of 
colitis. Sugimoto group shown amelioration of colitis in mice with TNBS-induced 
colitis treated with 0.5%, 2.0% or 5.0% of curcumin (added to their diet). 
Curcuma suppresses infiltration of effector T cells CD4 (+) and the activation of 
NF-kB in the colonic mucosa. It also suppresses the formation of 
proinflammatory cytokines in the colonic mucosa (21). Ukil demonstrates the 
protective role of curcuma in mice which developed a model IBD characterized 
by oxidative and nitrosative stress, by infiltration of leukocytes and 'upregolation' 
of proinflammatory cytokines that are commonly observed in human IBD (22). 
Salh group has found that when curcumin is administered before the induction of 
colitis it reduces the activation of NF-kB (23).  
Moreover, it has been observed that administration of curcumin to mice with 
TNBS induced colitis, prior to induction of colitis, is associated with a marked 
reduction of the expression of Th1 cytokines (IL-12, IFN-γ, TNF-α, IL-1) and to an 
increased expression of Th2 cytokines (IL-4 and IL-10) in the colonic mucosa. 
Few groups have attempted to study the role of Curcuma in IBD patients (24). 
In the pilot study of Holt, curcuma was administered in five patients with 
ulcerative colitis and five with Crohn’s disease. Each patient was administered 
orally 360 mg of curcumin three times a day for a month and then four times a 
day for two months. Of the 10 patients, 9 reported improved. Four of the five 
patients with ulcerative ulcersosa (UC) were able to reduce or to eliminate their 
complementary treatments. 
In a randomized double-blind multicenter Hanai has given to a total of 89 patients 
with a form of quiescent UC 1g of curcumin (n = 45) twice a day plus 
sulfasalazine or mesalamine as conventional drug reference to the treatment of 
patients with IBD. The remaining patients (n = 44) have, however, received the 
placebo plus sulfasalazine or mesalamine for six months. During the first six 
months of therapy, the 43 patients who received curcumin, two (4.65%) had 
relapse, while eight of the 39 patients (20.51%) in the placebo group (P = 0.040), 
showed relapse. The study of Hanai is the first multicenter study on curcumin in 
patients with quiescent IBD that have been proven safe and effective in 
prolonging the time in which patients may remain in quiescence, suggesting that 
it would be able to suppress recurrence. The obvious benefits to which this would 
lead to avoiding mortality associated with clinical relapse and reduce medical 
costs. 
Therefore, the inhibitory effects on the major inflammatory mechanisms such as 
COX-2, LOX, TNF-α, IFN-γ, NF-kB and its unparalleled safety profile, make a 
bright outlook of curcumin in the treatment of IBD. However, clinical studies are 
needed-controlled trial in a large cohort of patients to fully evaluate the clinical 
potential of curcumin. 
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Figure 4: Effect of curcuma in Experimental mice model of colitis (21-25). 
 
 
1.4  Myorelaxant effect of curcuma in a mouse model of colitis 
 
1.4.1  Background 
In patients with Inflammatory Bowel Disease the entire functionality of the ileum 
and colon is altered even when the disease involves specific intestinal segments. 
Inflammation is associated with a reduction in the formation of haustra and 
mixing of the colon with increased propulsive motility.  A change in cholinergic 
and adrenergic system as well non adrenergic non cholinergic system have been 
described in experimental amimals, the underlying mechanisms were 
disturbances of intracellular calcium signaling and mobility, altered release of 
norepinephrine, impairment of protease-activated receptor 2, defects relaxation 
dependent inhibitory neurons in the colon.  
The toxicity, intolerance to conventional therapy for IBD or the slow onset of 
action in addition to a more detailed understanding of the mechanisms that 
underlie the disease and its debilitating nature have been the main reasons that 
led to seek treatment safer and more effective. 
Curcuma longa (tumeric) is used in Ayurvedic medicine as a hepatoprotective 
agent and as a remedy for several inflammatory diseases. As already said, in 
traditional medicine has been used for its anti-tumor properties, antimicrobial, 
anti-inflammatory and antioxidant.  
Curcumin has been shown to be effective in trinitrobenzene sulfonic acid (TNBS) 
experimental mice model through inhibition of the most important of the 
inflammatory response in signal transduction such as AP-1, protein kinase C and 
NF-kB and, likewise, prevents inflammation in chronic colitis DSS (sodium 
dodecylsulfate)-induced by blocking the activation of NF-kB in the mucosa. In 
addition, turmeric, in a randomized, multicenter, double-blind, compared with 
placebo, was shown to be safe and effective in maintaining remission of 
ulcerative colitis. 
So far, there are a lot of data on anti-inflammatory properties of turmeric in 
humans and efficacy in preventing DSS-induced colitis in animals, but little is 
known of the effect of turmeric on intestinal motility (26-38). 
The extensive clinical use of Curcuma Longa for the treatment of diarrhea in 
western countries has led the current research in order to assess whether 
curcumin exerts a direct effect on the motility of the ileum and colon and whether 
this effect, if there was is observed, in addition to its anti-inflammatory effect in 
acute and chronic DSS colitis-induced mice. 
 
1.4.2  Methods 
Animals 
One hundred thirty male Balb/c mice (8 weeks old, 25–30 g b.w.) (Charles Rivers 
Laboratories, Calco, LC, Italy) were enrolled: a higher number of animals than 
required were recruited in order to compensate for the drops out in the course of 
the experiments, due to the severity of colitis compelling to stop the experiments, 
according to the Recommendations of the Ethical Committee of the University of 
Bologna for Animal Experiments. The animals were kept at constant light/dark 
cycling and constant room temperature of 22°C. They were fed the usual 
commercial diet. 
5 groups were created. A group of 15 healthy mice was used to evaluate the in 
vitro effect of Curcuma extracton on intestinal motility parameters by antagonism 
of Carbachol-induced contraction. A second and a third group of animals were 
subjected to Dextran Sodium Sulphate (DSS) (MP Biomedicals, Solon; OH, USA; 
m.w. 36.000–50.000). The effect of DSS on the Disease Activity parameters and 
intestinal motility were evaluated. After colitis induction, Curcuma extract was 
orally administered (200 mg/kg b.w./day).  14 mice were used as controls and 6 
mice were used as Curcuma fed control, after oral administration of Curcuma 
over seven days. Intestinal histology, spontaneously and Carbachol-induced 
motility were assessed in each mouse. The effect of Atropine in Carbachol-
induced contraction was also studied in order to get more insights into the 
mechanism of action of Curcuma extract on the ileal and colonic contraction. 
Study protocol 
The in vitro effect of curcuma was evaluated on isolated mice ileum and distal 
colon segments. Chronic colitis was induced by oral administration of DSS 
(2.5%, w/v) in drinking water while the animals were fed the usual commercial 
diet. At the 52nd day, Curcuma was administered to one group.  After colitis 
induction and after 7, 14, 21 days of either Curcuma extract added diet (200 
mg/kg/b.w.) or standard diet administration, 6 mice of each group were sacrificed 
and the following parameters were evaluated: colon length, intestinal histology 
and motility. Acute colitis was induced by addition of DSS (5% w/v) in the 
drinking water for 7 days. After this period, the mice were randomly allotted to 
two groups, one group continued the standard usual diet, the other was switched 
to a diet similar to the previous but added with Curcuma (200 mg/kg b.w.); after 7 
days, the animals were sacrificed.  14 mice were studied as controls. 6 mice 
were fed Curcuma added diet over 7 days and thereafter sacrified and similarly 
studied. (Figure 4). 
 
 
Figure 4 
Hematoxylin and eosin staining of Colon sections from DSS (5%w/v over 7 days) 
treated mice, before (a) and after 7 days Curcuma extract administration (b) and 
from DSS (2.5%,w/v, three cycles over 52 days) (c) and after 21 days Curcuma 
Acute and chronic colitis were induced by DSS administration according to Wirtz 
group and Disease Activity Index (DAI) was calculated as described by 
Fitzpatrick. Mice were on a 4RF21diet (Mucedola S.r.l., Milan, Italy). The 4RF21 
complete food was added with Curcuma (Indena Spa, Milan, Italy) extract at a 
final concentration of 1 g/kg. The delivery form of Curcuma used in the present 
study is a patented formulation of Curcumin (Free Curcumin; 
Curcuminglucuronide; Curcuminsulphate), a dietary phenolic, with soylecithin. 
The two compounds form a non-covalent adduct in a 12 weight ratio, and two 
parts of microcrystalline cellulose are then added to improve formulation. The 
chemical preparation was proved to be 18–22% pure by HPLC total 
curcuminoids content.   
The day prior to the experiments, food was withdrawn and water was maintained 
ad libitum. The animals were sacrificed by cervical dislocation. A portion of 
jejunum, immediately after the Treitz was removed (1.5 cm) and retained for 
histological examination. A 1.5 cm length segment of the terminal ileum, 
immediately proximal to the ileo-cecal valve and a 2.5 cm region of the distal 
colon were identified, slightly cleaned with Krebs solution to remove fecal 
residues and dissected into two parts: one part was placed in 10% formalin for 
subsequent histological analysis, a second was retained for immediate in vitro 
motility studies (see below). Stools were analyzed for consistency and blood 
traces. The sections of ileum and colon specimens were preserved in 10% 
neutral buffered formalin for about 48 hours and routinely processed. The 
histological preparations were examined histologically on a blinded basis. Acute 
colitis has intense inflammatory cell infiltrate, crypt abscesses, mucin depletion, 
and surface ulceration, that are the main histological features of acute activity. 
The hallmark is the presence of neutrophils and eosinophils infiltrating lamina 
propria and crypt epithelium. Chronic colitis is characterized chronic inflammatory 
cells, plasma cells and lymphocytes in the lamina propria, distortion of the normal 
architecture of colonic mucosa, including crypts branching and regeneration. 
Basal accumulation of lymphocytes and plasma cells with hyperplasia of 
lymphoid tissue probably represents an early immunologic manifestation of the 
underlying disease. 
Therefore, according to the amount of acute and chronic inflammatory cell 
infiltrate in colon and in small bowel slides colitis was classified in four grades as 
reported in Table 1. 
TABLE 1: Histological score 
0 absence of neutrophyls and eosinophils in the lamina propria. 
1 Mild and focal infiltrate of neutrophils and eosinophils in the lamina propria with 
mild crypt aggression. 
2 Moderate infiltrate of neutrophils and eosinophils in the lamina propria with 
moderate crypt aggression. 
3 Marked and diffuse infiltrate of neutrophils and eosinophils in the lamina propria   
with marked crypt aggression. 
 
The animals were sacrificed by cervical dislocation, and the organ (ileum and 
distal colon) required was set up rapidly under a suitable resting tension in 15 mL 
organ bath containing appropriate physiological salt solution (PSS) consistent 
warmed (see below) and buffered to pH 7.4 by saturation with 95% O2–5% CO2 
gas. The terminal portion of ileum (immediately proximal to the ileo-caecal 
junction) was cleaned, and segments 1 cm long of ileum were set up under 1 g 
tension at 37°C in organ baths containing Tyrode solution of the following 
composition (mM): NaCl, 145; KCl, 2.6; CaCl2·2H2O, 1.5; MgCl2·6H2O, 0.73; 
NaH2PO4·2H2O, 0.33; NaHCO3, 4.8; glucose, 11.1. Each segments was set up 
under 1 g tension in the longitudinal direction along the intestinal wall. Tissue 
were allowed to equilibrate for at list 30 min during which time the bathing 
solution was changed every 10 min. Concentration-response curves were 
constructed by cumulative addition of the agonist Carbachol (CCh). The 
concentration of agonist in the organ bath was added only after the response to 
the previous addition had attained a maximal level and remained steady. 
Contractions were recorded by means of displacement transducer (FT. 03, Grass 
Instruments, Quincy, MA) using Power Lab software. Controls not receiving any 
antagonist were used. Concentration–response curves to agonist were 
calculated at 30 min intervals, the first one being discarded and the second one 
used as control. A new concentration-response curve to agonist was obtained 
following incubation with the antagonist (Atropine or Curcuma extract). Tension 
changes were recorded isotonically. A segment of about 2 cm of the distal colon 
was transected, rinsed with Krebs solution of the following composition (mM): 
NaCl, 119; KCl, 4.5; CaCl2, 2.5; MgSO4·7H2O, 2.5; KH2PO4·2H2O, 1.2; 
NaHCO3, 25; glucose, 11.1; the mesenteric tissue was removed. The segments 
were suspended in organ baths containing gassed warm Krebs solution under a 
load of 1 g maintained at 37°C. Tension changes in longitudinal muscle length 
were recorded. Tissues were allowed to equilibrate for at least 30 min during 
which time the bathing solution was changed every 10 min. Concentration–
response curves to agonist Carbachol (CCh) were recorded isotonically and 
obtained at 30 min intervals, the first one being discarded and the second one 
taken as control. Following incubation with the antagonists (Atropine or Curcuma 
extract), a new concentration–response curve to agonist was obtained. 
Longitudinal muscle contractions were recorded isotonically by the mean of force 
displacement transducer (FT 03, Grass Instruments, Quincy, MA) using Power 
Lab software (ADInstruments Pty Ltd, Castle Hill, Australia). In all cases, parallel 
experiments in which tissues did not receive any antagonist were run in order to 
check any variation in sensitivity. 
 
Statistical Analysis 
pEC50 values represent the –logEC50. EC50 values are the means ± SE of at 
least four independent experiments and were calculated by a non-linear 
regression curve-fitting computer program. 
In functional experiments, dose ratios at the EC50 values of the agonist were 
calculated at three to five antagonist concentrations, and each concentration was 
tested from two to four times. The results are expressed as pA2 values . Data are 
presented as means ± SE of n experiments. Differences between mean values 
were tested for significance by Student’s t-test. P value less than 0.05 was 
considered significant. The antagonism activity to CCh of curcuma extract was 
estimated by determining the concentration of the non-competitive antagonist 
that inhibited 50% of the maximum response to the agonist. Three different 
antagonist concentrations were used and each concentration was tested at least 
three times. A pharmacological computer program was used to analyze data. It 
was always verified that EC50 values for the agonist in tissues receiving only the 
solvent were not significantly different (P>0.05) from control values. In other 
cases experiments were discarded.  
 
 
 
 
 
 
 
 
 
 
 
 
1.4.3 Results 
Histological parameters, colon length and DAI 
Both the ileum and the distal colon of the control mice demonstrated a very mild 
lymphocytic infiltration, typical for the “physiological inflammation”. 
  Histological Grading 
  After colitis 
induction 
After 7 
days 
After 14 
days 
After 21 days 
Controls  0 0 0 0 
Acutecolitis followed  
by 
standard 
diet 
3–3 2–3   
 Followed 
 by 
curcuma 
extract 
3–3 1–2   
Chronic 
colitis 
followed  
by 
standard 
diet 
3–3 2–3 2–3 2–2 
 followed  
by curcuma 
extract 
2–3 2–2 1–2 0–1 
 
Severe edema, inflammatory cells infiltration with granulocytes into both the 
mucosa and the submucosa, with destruction of the epithelial cells are the 
common features of Acute DSS-induced colitis. One week after discontinuation 
of DSS, mice assuming Curcuma has a lower histological score. 
In chronic DSS induced colitis, chronic inflammatory cells sometimes with mild 
neutrophil infiltrate were present in the mucosa and submucosa. 3 weeks after 
withdrawal, mice under Curcuma extract had a lower histological score.  
  
Effect of acute (a) and chronic (b) DSS administration on colon length:  a1) 
control. a2) acute colitis. a3) acute colitis treated with curcuma for 7 days. a4) 
acute colitis + standard diet for 7 days. b1) control. b2) chronic colitis. b3) chronic 
colitis treated with curcuma extract for 21 days. b4) chronic colitis + standard diet 
for 21 days.  
 
 
 
 DAI in the acute (a) and chronic colitis (b) model.  
 DAI in mice + curcuma (red) or + standard diet (black) after acute (a) and 
chronic (b) colitis induction. 
 
Spontaneous motility in ileum and colon 
The ileal and colonic contractions in basal conditions were used as control. In 
vitro curcuma extract inhibited the spontaneous intestinal contraction by 100%  in 
ileum and colon (Figure 5). In vivo, when orally administered over one week to 
control mice, there was a reduction of 30%. In acute model, there was increase 
of 230% in the ileum and the contractions were highly irregular in amplitude and 
frequency; colonic contractions were reduced of 100%. One week of Curcuma 
diet results in 50% of reduction in the ileum, while standard diet did not affect 
contractions. In chronic DSS colitis, spontaneous contractions increased by 
400% and 300% respectively in the ileum and colon. They were of irregular 
amplitude and frequency. Seven days after curcuma administration, a partial 
normalization was observed in both the ileum and the colon; 14 days after 
Curcuma administration the basal ileal and colonic motility were normalized and 
were of constant amplitude and frequency. A longer administration (21 days) 
inhibited the basal spontaneous activity of the ileum and colon. 
 
 
 
 Figure 5. Inhibition of spontaneous motility of ileum (upper panel) and 
colon (lower panel) by curcuma extract. In control conditions (a), after 
curcuma extract  (b) and after washing (c). 
Response to Carbachol and Atropine 
Experiments performed in mice ileum and colon showed that Curcuma extract 
inhibited the maximum response to Carbachol in a non-competitive manner. 
These results show that the extract produce a smooth muscle relaxation effect on 
mice ileum and colon. Furthermore, this blockade was reversed after 30 min 
tissue washing  (Figure 6). The IC50 value for Curcuma extract was 0.03 mg/ml 
in ileum and 0.04 mg/min distal colon respectively. In both cases, the agonist 
activity was comparable. In order to evaluate the effects of Curcuma extract on 
the intestinal muscular layers of ileum and colon, we have used as reference the 
contraction induced by Carbachol and the antagonistic effects of Atropine. Figure 
4 reports Carbachol pEC50 and Atropine pA2 on ileum and colon respectively. 
 
 
Figure 6 
Carbachol results more potent on the ileum than on the colon. Atropine has 
similar antagonistic activity on both tissues: these data have been used as a 
comparison with the effect of Carbachol and Atropine on tissues from DSS 
treated animals (acute and chronic colitis) and after Curcuma extract or placebo 
administration. 
 
 
Functional Study in DSS Mice Smooth Muscle 
Acute colitis 
Carbachol induced contraction was reduced: in the ileum Charbacol pEC50 
decreased by 3.80 times and in the colon by 1.58 times (Figure 7). 
 
Figure 7 
Similarly, the effect of Atropine was decreased: pA2 was reduced by 1.86 and 
1.12 times respectively in the ileum and the colon. Both the effects were stronger 
in the ileum than in the colon: This finding is at variance with the histological 
damage, which is limited to the colon, resembling the histopathological features 
of UC. Seven days Curcuma extract administration improved the response to 
Carbachol in the colon, but not in the ileum, both in comparison with the 
response of colon from mice with acute disease and mice assuming control diet, 
also if it did not completely restore the normal values. The response to Atropine 
was decreased both in the Curcuma added diet group and in the controls. In the 
ileum, Curcuma extract administration did not even partially restore the response 
to Carbachol and Atropine. In order to evaluate whether Curcuma extract had 
any effect on normal intestine and compare it, if any, with the effect of Curcuma 
on the intestine from mice with DSS induced acute colitis, we have administered 
Curcuma extract for 7 days to control mice. Curcuma extract inhibited the 
response to Carbachol in the ileum, by 1.69 and in the colon, by 1.20, while it 
increased in both the response to Atropine. The effect was greater in the ileum. 
   Standard Dieta CurcumaExt
b 
ileum CCh pEC50
c 
6.63±0.04 6.40±0.03 
 Atropine pA2d 8.89±0.03 9.16±0.02 
colon CCh pEC50
c 
6.08±0.01 6.00±0.01 
 Atropine pA2d 8.89±0.01 9.47±0.02 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic colitis 
Chronic colitis was induced in mice with DSS (2.5%w/v), three “8 days” cycles, 
with plain water between, for a total of 52 days, after which one group continued 
the control diet for 7 days, the other was switched to curcuma (200 mg/kg/day) 
over 7 days. After colitis induction, animals were either switched to curcuma or 
continued the usual diet. They were then sacrificed after 7, 14, 21 days and the 
two groups of animals were compared (Figure 8). 
 
 
 
 
Figure 8 
 
 
 
 
Discussion 
There are few data available concerning the relationship between Curcuma and 
intestinal motility. In healthy humans, an indirect evidence that Curcuma 
activates bowel motility has been produced by hydrogen breath. On the contrary, 
Curcuma increases intestinal transit time in albino rats and ileal motility in Guinea 
Pig. The use of turmeric as an anti-inflammatory agent in IBD and the traditional 
empiric use of Curcuma as an antidiarrheal symptomatic drug in functional 
disorders of the gastrointestinal tract suggested an effect on intestinal motility. In 
IBD altered motility does not correspond to the location of inflammation and a 
reduced sympathetic regulation in uninflamed intestinal tracts has been 
demonstrated (39). The development of intestinal dysmotility may in turn result in 
abnormal growth of intestinal microflora, subsequently inducing a translocation of 
bacteria or bacterial products through the impaired mucosal barrier (40). 
In humans, it is not clear whether IBD is associated with hyper or hypomotility 
(41). Reduced haustra formation, but augmentation colonic propulsive motility 
and diarrhea have been described (42,43). DSS colitis shares clinical and 
histopathological features of UC and reproduces a model of chemically driven 
colitis, where the damage of the epithelium is related to inflammation without an 
immune component. This model represents a good way to induce inflammation in 
the colon and to study its effect on motility. Spontaneous phasic contractions and 
Carbachol-evoked contractions of distal colon smooth muscles are reduced in 
DSS model of colitis (43,44). Conversely, increased Carbachol-evoked 
contractions and colonic smooth muscle hypercontractility were reported (45). 
These findings may correlate with differences in experimental conditions, strain 
and gender differences in the susceptibility of DSS-colitis. In view of the possible 
gene differences, we have used male Balb/c mice: Balb/c mice are a strain 
commonly used for all-purpose laboratory investigations. Moreover males have 
been preferred over females to avoid the phasic influences of sexual hormones 
on gastrointestinal motility. In the present investigation, DSS induces deep 
disturbances in basal motor activity of ileum and colon: it is worthwhile noting that 
in acute colitis a hyperexcitability of the ileum is observed associated with a 
depressed motor activity in the colon, while a severe hyperexcitability is present 
both in ileum and in colon in the chronic colitis model. The abolition of any motor 
activity of the colon in acute experimental colitis is in agreement with the clinical 
condition of the toxic megacolon. We have chosen as reference of disturbed 
motility the ileal and colonic response to Carbachol and the inhibitory effect of 
Atropine on the Carbachol induced contraction. Carbachol and Atropine are 
respective agonist and antagonist at cholinergic muscarinic receptors. Both 
agonist and antagonist bind to the cholinergic receptors M(2) and M(3), present 
in mice small intestine and colon cellular membrane. In the present investigation, 
we have induced both chronic and acute colitis in mice, since the chronic model 
is more suitable for Curcuma treatment. The muscarinic receptor agonist 
Carbachol generated a smaller contractile force in the DSS-treated mice than in 
normal mice both in inflamed strip and uninflamed.  
In this study we show that, in control conditions, Carbachol effect is more potent 
in the ileum than in the colon, while the antagonistic effect of Atropine is similar. 
In vitro, Curcuma inhibits intestinal basal and Carbachol induced contraction in a   
non-competitive and reversible manner. The inhibition of basal intestinal motility 
demonstrates a direct effect on the intestinal muscular cells. The inhibition of 
Carbachol response is stronger in the ileum while the antagonistic effect of 
Atropine is increased in both. When orally administered to healthy animals, 
Curcuma has similarly shown a direct myorelaxant activity and an inhibition of 
Carbachol response on the ileum and colon, stronger on the former than on the 
latter. The effect of Atropine is conversely increased on both the intestinal tracts. 
These data represent the first attempt to characterize the myorelaxant effect of 
Curcuma longa on the ileum and colon. We have shown that this effect is 
independent of the anti-inflammatory effect. The mechanism of action is due both 
to a direct myorelaxant effect on the intestinal muscle layers and to a non-
competitive and reversible inhibition of the cholinergic agent. The present study 
provides the rationale for the use of Curcuma Longa in motility disorders of IBD 
and suggests a possible application to functional motor disturbances of the 
gastrointestinal tract, due to the myorelaxant effect on the normal intestine, 
independent of the anti-inflammatory activity. 
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2. Characterization of the role of CEACAM5 in the intestinal 
immuneregulation 
2.1  BACKGROUND 
The intestinal epithelial barrier is a dynamic structure that separates the intestinal 
luminal content (antigens from the diet and microbioma) from the underlying 
immune system in the lamina propria. It is a mechanic barrier itself because 
regulate the antigens trafficking by its nature and composition and because it 
regulates the crosstalk with the cell of the immune system. Epithelial cells are 
placed at the center of this structure. On the luminal side they regulate nutrient 
absorption as well as mucous layer composition; on the basolaterl side they talk 
with the immune cells. 
Mayer’s lab among others has well demonstrated the role of intestinal epithelia 
cells as non-professional antigen presenting cells (Figure1). 
The nature of the immune response in the intestine is one of immunosuppression 
or controlled inflammation. The suppressive state is dictated by several factors 
including regulatory T cells, non-T cells and unique antigen presenting cells. It is 
well known that failure to control immune responses may lead to inflammatory 
bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC). In 
the normal colon, it has been suggested that the immunosuppressed state may 
be related to unique population of antigen presenting cells and unique 
populations of T cells.  
 
 
                            
Figure 1: The epithelial barrier system. A: Normal epithelial barrier; B: 
Inflammatory bowel disease (IBD) epithelial barrier. TLR: Toll-like receptors; 
MyD88: myeloid differentiation factor 88; TJ: Tight junctions. World J. 
Gastroenterol. 2010 September 14; 16(34): 4264–4271 
Our lab has proposed that IECs can act as nonprofessional antigen presenting 
cells. We have described that IECs interact with T cells through a unique 
complex, formed by a carcinoembryonic antigen-related cell adhesion molecule 
(CEACAM) subfamily member (gp180) and the nonclassical class I molecule 
CD1d resulting in the expansion of CD8+ T regs. (1-7). We characterized gp180 
as a surface glycoprotein recognized by two anti-epithelial cell mAbs, B9 and 
L12. We demonstrated that gp180 (mAb B9 affinity purified material) binds to 
CD8, activates CD8 associated kinase p56Lck and binds to CD1d.  The two 
mAbs (B9 and L12) block the selective proliferation of CD8+ T cells and inhibit 
the phosphorylation of the CD8 associated kinase p56Lck in IEC: T cell co-
cultures (8-17).  Furthermore, we documented decreased expression of gp180 in 
non-inflamed IBD tissues with mAb B9. This defect correlated with the inability of 
IBD IECs to activate CD8+ Treg cells (18). 
CEA (CEACAM5) was first described in 1965 by Gold and Freedman as a tumor 
associated antigen in human colon cancer tissue extracts. It was hypothesized 
that CEA was an oncofetal antigen – expressed during fetal life, absent in healthy 
adult and re-expressed when epithelial cells became malignant. Nowadays, it is 
well established that CEA is expressed in adult tissue as well. The CEA gene 
family belongs to the immunoglobulin gene superfamily. Two subgroups exist: 
CEA and the pregnancy specific glycoprotein (PSG) subgroups. CEA subfamily 
proteins are cell surface proteins whereas the PSG are secreted proteins. CEA 
subfamily proteins are heavily glycosylated and can be either transmembrane or 
GPI-linked. Analysis of the amino acid sequence reveals distinct domain 
organization amongst the family. Two types of immunoglobulin (Ig) domains are 
seen: an N-terminal domain of 108 amino acids homologous to the Ig variable 
domain (IgV-like) and between zero and six domains homologous to the Ig 
constant domain to the C2 set (IgC-like). The IgC domain may be either of type A 
containing 92 amino acids or type B containing 85 amino acids. According to this 
designation the domain formula is N-A1-B1-A2-B2-A3-B3. CEA is expressed in 
columnar intestinal epithelial cells and goblet cells in the colon, in mucous neck 
cells and pyloric mucous cells in the stomach, in squamous epithelial cells from 
the tongue, esophagus and cervix, in secretory epithelia, and ducts cells of sweat 
glands and in epithelial cells from the prostate. CEA has been described to play a 
role in cell-cell adhesion through homotypic and heterotypic anti-parallel N-
domain to N-domain interactions or N-domain to membrane proximal domain 
(two points of interaction between two neighboring cells). Moreover, CEA 
functions as signal transduction through the modified ITAM (immunoreceptor 
tyrosine-based activation domain)/ITIM (immunoreceptor tyrosine-based 
inhibition motif) in a long cytoplasmic tail isoform of transmembrane CEA 
subfamily proteins. Various reports have described a role for CEA family 
members in cell-cell adhesion engaging homotypic and heterotypic interactions 
through their N-terminal domains. Several members have been described to act 
as pathogen sensors suggesting a possible role of CEA in host-pathogen 
crosstalk. (19-29). 
 
 
  
Figure 2: CEACAM family members. Mucosal Immunology (2008) 1 (Suppl 1), 
S39–S42. doi:10.1038/mi.2008.50 
 
 
Our hypothesis guiding this proposal is that gp180 is CEACAM5, one of the 
member of the CEACAMs family and that an unique set of interactions between 
CEACAM5 and CD1d form a complex that binds to CD8 and the TcR and results 
in the activation of CD8 Tregs. In fact, defining the nature of the intermolecular 
interactions between CEACAM5, CD1d and CD8 will help to identify the 
mechanism of activation of TrE cells and to develop mechanisms to promote this 
interaction in Crohn’s disease, where we have shown a defect in the activation of 
CD8+ Treg cells (related to a defect in the expression of CEACAM5). 
Furthermore, as a result of these studies, we can enhance mucosal immunity (as 
in CEACAM5 expressing tumors) by blocking the interaction of CEACAM5 with 
CD8 with interfering small peptides. Understanding the role of CEACAM5 in the 
mucosal immune system in normals will allow us to define the nature of the 
defects in expression of these molecules in IBD and potentially develop 
approaches to overcome the defects seen. We will initiate these studies by 
determining how CEACAM5 is involved in the activation of CD8+ regulatory T 
cells and assessing whether the B9 binding site on CEACAM5 overlaps with the 
CD8 binding site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 SPECIFIC RESEARCH OBJECTIVES 
Specific Aim 1. Assess whether gp180 is homologous to CEACAM5. 
Specific Aim 2.  Define CEACAM5/CD1d interactions.  
Specific Aim 3. Define CEACAM5/CD8α interaction and CEACAM5 
functionality. 
Specific Aim 4. Assess whether mutation in the N domain of CEACAM5 affect 
CEACAM5/CD8α interaction 
Specific Aim 5. Design small (CEACAM5) peptides from the N domain and 
assess their ability to activate CD8-associated LcK kinase. 
  
 
2.3 METHODS OF APPROACH 
Purification and sequencing of gp180 
gp180 purification from human intestinal epithelial cells (IECs) was performed 
using a mAb B9 affinity column as described previously (8). Protein sequencing 
was accomplished by the Protein DNA Core at the Rockefeller University.  
Construction of vectors  
Dual expression vector of CEACAMs and CD1d: cDNAs for CEACAM1, 
CEACAM5, CEACAM6 and CD1d (Genbank accession no NM_001024912, 
NM_004363, NM_002483 and NM_001766) were obtained by RT-PCR from 
human IEC mRNA.  All of the primers are shown in Table 1.  
 
 
  
Table 1: CEACAMs  and CD1d primers sequences 
 
 
An internal ribosomal entry site (IRES) was amplified from the pIRES-EGFP 
plasmid (Clontech) using forward (5’-CCGAATTCATTCCGCCCCTCTCC-3’) and 
reverse (5’-CCGGATCCGGGTTGTGGCAAGC) primers. Then the IRES alone 
(IRES), IRES-CD1d (CD1d), IRES-CEACAM5-GFP as well as IRES-CD1d 
simultaneously with CEACAM1, CEACAM5 or CEAMCAM6 (CEACAM1.CD1d, 
CEACAM5.CD1d and CEACAM6.CD1d) were subcloned into pcDNA3.1(-) vector 
(Invitrogen).  
Vectors expressing mutants of CEACAM5: Wild-type (WT) CEACAM5 construct 
was used as a template for PCR-generated mutant constructs. For sequential C-
terminal truncation, the forward primer for WT was used and the reverse primers 
for all the deletion mutants including B3, A3B3, B2A3B3, B3.1, B3.2, B3.3, B3.4, 
B3.5 are shown in Table 2.  
 
 
 Forward Reverse 
CEACAM1 5’-CCGCTAGCATGGGGCACCTCTC-3’ 5’-CCCTCGAGTTACTGCTTTTTTAC-3’ 
CEACAM5 5’-CCGCTAGCATGGAGTCTCCCTC-3’ 5’-CCCTCGAGCTATATCAGAGCAAC-3’ 
CEACAM6 5’-CCCTCGAGCTATATCAGAGCAAC-3’ 5’-CCCTCGAGCTATATCAGAGCCAC-3’ 
CD1d 5’-CCGGATCCACCATGGGGTGCCTGCTG-3’ 5’-CCCTTAAGTCACAGGACGCCCTG-3’ 
 Table 2: ΔB3, ΔA3B3, ΔB2A3B3, ΔB3.1, ΔB3.2, ΔB3.3, ΔB3.4, ΔB3.5 primers 
sequences 
 
Overlap extension PCR was performed to construct the expression vector for 
deletion of the A2-domain. The forward primer for the WT CEACAM5 and 
reverse primer (5’-GACGACCCCACCATTTCCCCCTCA-3’) were used to 
generate fragment 1. The forward primer (5’-
GGTGGGGTCGTCGGGTGGCTCTGCATA-3’) and reverse primer for WT 
CEACAM5 were used to generate fragment 2. Then the cDNA with the deletion 
of A2-domain was generated from fragment 1 and 2 using primers for WT. The 
PCR fragments were subcloned into CD1d-pcDNA3.1(-). The p91023(B) vectors 
encoding WT and mutant CEACAM5 with deletion of N42 to I46 residues in the 
N-terminal domain (N42RQII), point mutations in the N-terminal domain (K35A 
and N70,81A) and CEACAM8 were generated. The sequences of all constructs 
were confirmed by DNA sequencing. CD8α cDNA was provided by Dr P. 
 Reverse 
ΔB3 5’-GCGGCCGCCTACGGCCCATAGAGGACATCCAGG-3’ 
ΔA3B3 5’-GCGGCCGCCTAGGGCAGCTCCGCAGAGACTGTGAT-3’ 
ΔB2A3B3 5’-ATAGCGGCCGCCTATGGGCCATAGAGGACATT-3’ 
ΔB3.1 5’-ATAGCGGCCGCCTAGCCAGTAGCCAAGTTAGA-3’ 
ΔB3.2 5’-ATAGCGGCCGCCTAATTATTTGGCGTGATTTT-3’ 
ΔB3.3 5’-ATAGCGGCCGCCTATTGCTGCGGTATCCCATT-3’ 
ΔB3.4 5’-ATAGCGGCCGCCTATGGGTTAGAGGCCGAGT-3’ 
ΔB3.5 5’-ATAGCGGCCGCCTAGTAAGACGAGTCTGGG-3’ 
Kavathas (Yale School of Medicine) and the extracellular domain was sub-cloned 
into a pcDNA 3.1/V5-His vector. 
Cell culture and transfection 
For transfection, a human embryonic kidney (293T), an ovarian Chinese hamster 
carcinoma (CHO) and a melanoma (FO-1) cell lines were used. The cells were 
grown at 370C in Dulbecco’s modified Eagle’s medium (GIBCO, Carlsbad, CA) or 
in F-12K medium (ATCC) containing 10% fetal bovine serum (FBS), in a 
humidified 5% CO2 incubator. Cells were transfected in 6-well plates using 
Lipofectamine-2000 (Invitrogen) with 4 µg of pcDNA3.1 vectors encoding CD1d 
alone or along with wild-type or truncated CEACAM5. Untransfected or cells 
transfected with IRES were used as controls. For the generation of stable cells 
expressing wild-type and mutant CEACAM5, cells were transfected in 100 mm 
culture plates with 12 µg of p91023(B) expression vectors encoding wild-type or 
mutant CEACAM5 together with 12 µg of pcDNA3.1. The stable cells were 
established after selection with 3 mg/ml Geneticin (G418, Sigma). Stable cells 
were treated with 0.1unit/ml phospholipase C, phosphatidylinositol specific 
enzyme (PIPLC, Sigma) for 1 h at 37oC. The supernatant was collected and 
subjected to Western blotting using mouse Col-1 and mouse anti-gp180 (B9) 
monoclonal antibodies. Human IEC cell lines, HT29 and T84, were used as 
positive controls. 
Western Blots 
The protein samples were subjected to 10% SDS-PAGE gels, transferred to 
nitrocellulose membranes and blocked with 5% milk for 1 h at room temperature. 
Membranes were incubated with primary antibodies overnight at 4oC, washed 
with (phosphate buffered saline) PBS containing 0.05% Tween-20, and 
incubated with HRP-conjugated secondary antibody (Cell Signaling) for 1 h at 
room temperature. The proteins were visualized using a chemiluminescent HRP 
substrate (Millipore). 
Flow cytometry 
Trypsinized transfected CHO cells (1 x 106) expressing CEACAM5, 1, 6 and 8 
were incubated with the appropriate mAbs B9 and B18 diluted in 100 µL PBS 
containing 0.2% FBS and followed by a second incubation on ice with FITC-
labeled F(ab)’2 fragments of immunosorbent-purified goat anti-mouse IgG.  
3G8 cells were treated for different time points (2, 8, 10, 15 min) at 370C with 
anti-CD8 mAb (OKT8) at 5 ug/uL, H2O2 at 10 mM, CEACAM5 supernatant (Sup1) 
from PIPLC-293Tcells expressing CECACAM5 and purified CEACAM5 peptide 
at 20ug/mL. Stimulation was stopped by fixing with 4% formaldehyde for 10 min 
at room temperature. Subsequently, cells were permeabilized with ice-cold 
methanol for 20 min, washed with PBS containing 0.2% FBS and stained with 
anti-phospho-Lck Ab (BD Bioscences). The cells were then re-suspended in PBS 
plus 0.2% FBS, data acquired using the FACScan system and data analyzed 
with FlowJo analysis software. 
Co-immunoprecipitation 
293T cells were used for co-immunoprecipitation 48h after transfection with the 
corresponding vectors as described above. Cell extracts (150 µg of protein) were 
incubated with either 2 µg of mouse IgG2b anti-CD1d (D5), mouse IgG1 anti-
gp180 (B9), isotype control mouse IgG2b or mouse IgG1 for 4h at 4oC, followed 
by the addition of 10 µl protein G Sepharose (Amersham Biosciences) for 12h.  
Pellets were washed three times with RIPA buffer (10 mM Tris, pH 8.0, 1.0 mM 
EDTA, 0.5% Nonidet P-40, 0.1 M NaCl), boiled in SDS sample buffer, and 
resolved on SDS-PAGE gels. After transferring to nitrocellulose, an anti-CEA 
mAb (Col-1) (Dako) followed by a CD1d mAb D5 Western blot was performed.  
Absorption assay 
10 µL of PIPLC treated supernatants from 293T/CEACAM5 cells or from 
confluent T84 cells were incubated on ice with 14 x 106 3G4 (mouse T cell 
hybridoma transfected with human CD4 cDNA) or 3G8 (mouse T cell hybridoma 
transfected with human CD8 cDNA) cells for 1 hour. After incubation, 20 µL of 
RPMI were added to each tube to facilitate collection of the absorbed 
supernatants. Supernatants (Sup2) were collected following centrifugation at 
13,000 rpm for 2 minutes. The entire 30 µL was resolved in 8% SDS-PAGE and 
subjected to Western Blot analysis. 5 x 106 3G4 cells or 3G8 cells re-suspended 
in 50 µL of serum free RPMI medium were incubated on ice for 30 minutes, then 
co-incubated for 2, 8 or 15 minutes at 37oC with 293T/CEACAM5 or 293T/vector-
PIPLC (equivalent of 2 x 106 cells) bound to protein G-sepharose 4B beads via 
anti-CEA mAb Col-1 and rabbit anti-mouse IgG (RAM) (10µL beads medium). 
3G4 or 3G8 cells kept on ice were used as controls. At the end of each time 
point, samples were placed on ice; ice-chilled stop buffer added and samples 
were centrifuged at 13,000 rpm for 1 minute at 4oC. Supernatants were 
completely removed; cell pellets were immediately lysed in SDS-PAGE sample 
loading buffer and samples were subsequently subjected to Western Blot 
analysis using a horseradish peroxidase conjugated-4G10 (anti-phospho-tyrosine 
mAb) as the probing antibody. The same membrane was re-probed for lck and 
beta-actin, as internal loading controls.  
Protein purification 
The supernatant obtained from treated PIPLC transfected CHO cell lines was 
collected and subjected to mouse anti-CEA (Col-1) mAb Western blot. 
Supernatants expressing CEA were subjected to a Col-1 Ab (A/B domain 
specific) purification column, to dialysis using dialysis membrane tubing with 
MWCO of 12000-14000 and to concentration using Vivaspin 6 columns. 
Supernatant obtained from CD8α transfected 293T cells containing the 
extracellular domain of CD8α was collected and subjected to a mouse 
monoclonal anti-CD8α Antibody Western Blot. Supernatant expressing CD8α 
was purified using the Probond purification System-Invitrogen specific for 
polyhistidine-containing recombinant proteins. Eluted protein was then subjected 
to dialysis and concentration. Eluted proteins were finally subjected to mAb Col-1 
(Zymed) and mAb CD8α Western Blot (Santa Cruz) to confirm the presence of 
full length and mutants CEACAM5s and CD8α. 
Biacore Kinetic Analyses 
As assay buffer, we used 10 mM HEPES buffer (pH 7.4), 150 mM NaCl, 3mM 
EDTA, 0.005% P20 (polyoxyethylenesorbitan); as regeneration buffer we used 
50mM Tris, 2M NaCl, pH 7.3 and as conjugation buffer we used 10 mM sodium 
acetate buffer (pH 5.0). Purified CD8α protein was directly immobilized to the 
high capacity carboxymethylated dextran and covalently attached to a gold 
surface (CM5 chip) by amine coupling chemistry. The amount (RL) of protein to 
be captured on the chip was determined by the following formula: RMax=MWA / 
MWL • RL where MWA is the molecular weight of the analyte (CEACAM5) (180 
KDa) and MWL is the molecular weight of the ligand (CD8α) (19 KDa). RMax 
corresponds to the maximum resonance unit that we obtained during analyses. 
We set RMax below 50 for antibody/antigen interactions.  RL corresponds to the 
refractory index of the ligand and is expressed in resonance units (RU). RMAX of 
50 was RL = 50 x 19 / 180 = 5.3. We captured the ligand onto the chip until it 
reached 5.3 RU. RU is a Resonance Unit generated by the shift of refractory 
index due to ligand-analyte interactions on a sensor chip. KD is defined as KD = 
Kd/Ka. 
Biacore measures real time Ka (on rate) and Kd (off rate) based on its curve 
fitting program. The flow rate used for capturing ligand is 5 ml/min.  For kinetic 
analysis, the flow rate of 30 ml/min is used for the analyte. The first run is the 
scouting analysis using high concentrations of analyte. For the assays we used 
200 nM. At this concentration, binding should be observed even if the ligand 
binding affinity is weak. The scouting analysis provides a rough KD. Based on the 
rough KD value, full kinetics analyses are performed using 5 analyte 
concentrations slightly above the KD to zero. Chi square (χ2) analysis on the KD 
values obtained from each analyte concentration was performed to determine the 
statistical accuracy of the measured KD. χ2 value of ~2 is considered significant 
(accurate) and below 1 is highly significant (highly accurate). After each assay, 
the chip is treated with 50mM Tris, 2M NaCl, pH 7.3 to remove the ligand and the 
analyte for regeneration. 
 
2.4 RESULTS 
Purified gp180 bears sequence homology to CEA  
gp180, purified by immunoaffinity using mAb B9, was subjected to amino 
terminal sequencing by Edman degradation. Over the first 25 amino acids, there 
was 100% sequence homology with CEACAM5. The sequences of other 
CEACAM family members were similar but show clear differences with the 
sequence obtained. The congruence between the molecular weights and the N-
terminal amino acid sequences between gp180 and CEACAM5 strongly supports 
the contention that gp180 and CEACAM5 are identical.   
gp180            LTIESTPFNVAEGK--  LLLVHNLPQXLF  
                       LTIESTPFNVAEGK     LLLVHNLPQ   LF 
CEACAM5     LTIESTPFNVAEGKEVLLLVHNLPQHLF  
 
CEACAM5 transfectants express the B9 epitope  
Given the amino acid sequence homology to CEACAM5, we determined whether 
this member of the CEA family expressed the epitope recognized by mAb B9.  A 
CEACAM5-GFP bicistronic construct was transfected into 293T cells and FO-1 
cells.  GFP expressing 293T cells co-expressed a molecule recognized by mAb 
B9 (Figure 3). In addition, CHO cells transfected with CEACAM5 were shown by 
FACS analysis to bind mAb B9 (Figure 4).  These data suggest that CEACAM5 
contains the B9 epitope. 
 
                 
 
Figure 3: CEACAM5 is recognized by B9 mAb  
Immunoblotting for CEACAM5 in lysates obtained from HT29, as well as FO-1 
and 293T cells transfected with CEACAM5. B9 and Col-1 monoclonal antibodies 
were used for Western blotting. Non-transfected FO-1 and 293T cells were used 
as negative control. Data are representative of three independent experiments. 
 
mAb B9 recognizes other CEACAM family members 
CHO cells transfected with CEACAM6, CEACAM1-4L (a splice variant of BGP) 
and CEACAM8 were stained with two mAbs B9 and B18 and analyzed by flow 
cytometry.  In addition to CEACAM5, mAb B9 recognized CEACAM6, 
CEACAM1-4L, and CEACAM8 transfectants but not a non-transfected CHO cell 
line (Figure 4). Thus several CEACAM family members share the B9 epitope in 
their N-domains and could conceivably share the immunosuppressive function of 
CEA.     
 
Figure 4: B9 recognizes different CEACAMs expressed on IECs 
Cyto-fluorimetric profiles of CHO cells expressing CEACAM5 or CEACAM1-4L, 
CEACAM6 and CEACAM8, labeled with B9 or B18 mAbs. B9 can recognize all 
four CEACAM members. Data are representative of three independent 
experiments. 
 
CEACAM5 binds to CD1d through the B3 domain  
To assess whether CEACAM5 binds CD1d as well as gp180 and which member 
of the CEACAM family has binding properties to CD1d, we co-expressed different 
CEACAMs and CD1d in 293T cells. The lysates were subjected to co-
immunoprecipitation experiments using the anti-CD1d antibody D5. We show for 
the first time that CEACAM5 is the only CEACAM member expressed on IECs 
which interacts with CD1d (Figure 5).  
 
  
Figure 5. CEACAM5, but not CEACAM1 or CEACAM6 binds to CD1d. 
293T cells were co-transfected with pcDNA3.1-IRES-CD1d alone or together with 
CEACAM1, CEACAM5 or CEACAM6. The cell lysate was co-immunoprecipitated 
with mouse IgG2b anti-CD1d (D5), or with mouse IgG1 anti-gp180 (B9) 
antibodies.  Western blots were performed with Col-1 and D5 mAbs.  Data are 
representative of three independent experiments. 
 All CEACAM family members contain an extracellular N-terminal IgV-like and 
various C-terminal IgC-like domains that are designated as type A or B domains. 
We compared the sequences of CEACAM1, 5, and 6 and limited homology  in the 
A2 and B3 (B1 for CEACAM1 and CEACAM6) domains was found.  We 
generated different deletion mutants of CEACAM5. Neither deletion of the N-
terminal region nor of the A2 domain contributes to the interaction between 
CEACAM5 and CD1d (Figure 6). In contrast, sequential C-terminal truncations of 
each domain allowed us to determine that deletion of the B3-domain obliterated 
the ability of CEACAM5 to bind to CD1d (Figure 6). We then performed sequential 
deletions within the B3 domain and we found that the interaction between CD1d 
and CEACAM5 depends upon the integrity of fragments 2 to 5 of the B3 domain. 
(Figure 6). 
 Figure 6. The B3 domain of CEACAM5 interacts with CD1d. 
293T cells were transfected with expression vectors pCDNA3.1-IRES expressing 
CD1d and wild-type or truncated CEACAM5. The cell lysate of the transfectants 
was immunoprecipitated with mouse IgG2b anti-CD1d (D5). Western blot was 
then performed with Col-1 and D5 mAbs.  (a,b) WT and CEACAM5 with the 
deletion of N-domain (N) co-immunoprecipitate with CD1d. WT and CEACAM5 
with the deletion of A2-domain (A2) co-immunoprecipitate with CD1d. (c) 
CEACAM5 with the sequential C-terminal truncations of each domain fails to co-
immunoprecipitate with CD1d. (d) CEACAM5 with the deletion of fragment 1 of 
B3-domain co-immunoprecipitates with CD1d. With further deletion of the B3 
domain, CEACAM5 fails to co-immunoprecipitate with CD1d. Data are 
representative of three independent experiments. 
CEACAM5 binds to CD8α chains and induces CD8 associated kinase 
p56Lck phosphorylation  
CEACAM5 exists as a glycophosphatidyl inositol (GPI)-anchored glycoprotein on 
the surface of IECs.  The molecule can therefore be removed by cleaving the 
anchor with the enzyme PIPLC as previously described (8). CEACAM5 released 
from transfected 293T cells by PIPLC treatment was used in a series of 
absorption studies.  Murine T cell hybridoma transfectants expressing either 
human CD4 (3G4) or human CD8α (3G8) were cultured with PIPLC supernatants 
from CEACAM5 or vector control 293T cell transfectants.  Absorption of 
CEACAM5 from the supernatants by either CD4 or CD8 was determined by 
immunoblotting using mAb B9.  Human CD8α but not CD4 transfected 
hybridoma cells were capable of absorbing the B9 reactive material (Figure 7). 
These findings are consistent with functional properties previously ascribed to 
gp180. We next wanted to determine whether binding to CD8 had functional 
significance, evaluating CEACAM5’s ability to induce CD8 associated kinase 
p56Lck. An anti-phosphotyrosine Western Blot revealed more pronounced 
phosphorylation of p56Lck from CEACAM5 and 3G8 co-incubation than from 
CEACAM5 and 3G4 co-incubation. These data suggest that not only could 
CEACAM5 bind specifically to CD8 but also induce phosphorylation of CD8 
associated p56Lck similar to the functional effect of gp180 (Figure 7). 
 
Figure 7 
A. 3G4 and 3G8 cells were incubated with PIPLC supernatants from CEACAM5 
transfectants, vector control 293 T cells, or IECs cell line T84. FO-1 cells were 
used as negative control. Absorbed or unabsorbed supernatants were subjected 
for immunoblotting using Col-1 or B9 mAbs.   3G8 but not 3G8 were capable of 
absorbing CEACAM5. 
B. 3G4 and 3G8 cells were incubated with 293T/CEACAM5 or 293T/vector- 
PIPLC supernatants and subjected to immunoblotting for anti-phosphotyrosine 
mAb. OKT8 (anti-human CD8 antibody) and FFB2.3 (anti-human CD4 antibody) 
were used as positive controls. 3G8 cells incubated with CEACAM5 supernatants 
show more pronounced phosphorylation of p56Lck. 
 
Biacore analysis of CEACAM5-CD8α binding  
Binding of wild type CEACAM5 and CD8α was evaluated using Biacore. In this 
system, one molecule (in our case soluble ligand CD8α or CD4 (as a control) is 
immobilized on a dextran matrix and the putative analyte is passed over the 
surface in solution (in our case CEACAM5 wild type or mutants). A full kinetic 
analysis of wild type CEACAM5/CD8α binding revealed that CEACAM5 interacts 
with CD8α with an equivalent affinity to CD8α/MHC I interactions (Figure 8A) (30, 
31). Kon is 2.60E+04 M-1s-1 and Koff is 5.60E-04 s-1. The derived affinity 
constant is 2.20E-08 M. Binding was observed at a 50 nM concentration of the 
wild type CEACAM5. No binding was observed between wild type CEACAM5 
and a recombinant CD4 protein (Figure 8B). We next assessed whether the 
N42RQII deletion of CEACAM5 affects binding to CD8α.  Biacore analysis 
showed a reduction in the KD when compared with the wild type (N42RQII-
KD=1.70E-08 M; Kon=9E+04 M-1s-1; Koff=1.5E-03 s-1) (Figure 8C).  
Subsequently we compared the affinity of wild type CEACAM5/CD8α interactions 
with the CEACAM5 mutants. The affinity of N70,81A CEACAM5/CD8α binding 
(KD=1.60E-05 M) appeared to be the lowest when compared to the wild type 
CEACAM5 with a lower Kon ( 2.90E+02 M-1s-1) and a lower Koff ( 4.70E-03 s-1 
). Similarly, the K35A KD was decreased (KD 1.50E-07 M) with a Kon of 
1.50E+04 M-1s-1 and a Koff of 2.30E-03 s-1 (Figure 8C). 
These results suggested that the loss of the glycosylation affects the 
conformational structure of CEACAM5, thus resulting in a reduction in affinity 
between CEACAM5/CD8. 
 
 
Figure 8 
Binding of soluble wild type CEACAM5 (A) to immobilized CD8α peptide and of 
wild type CEACAM5 to immobilized recombinant CD4 peptide (B). KD values of 
binding of WILD TYPE CEACAM5, N42RQII, K35A and N70,81A to immobilized 
CD8α peptide are shown in panel C. 
 
mAb B9 blocks CEACAM5/CD8 binding  
To finally demonstrate the partial overlap between mAb B9 and CD8 binding site 
on CEACAM5, we premixed CEACAM5 peptide with mAb B9 and consecutively 
added the mixture to CD8α on the chip. As expected, no binding was observed 
(Figure 9). 
 Figure 9. B9 blocks CEACAM5-CD8α binding 
(a) Binding of soluble WT CEACAM5 to immobilized CD8α peptide. (b) Binding of 
B9 to immobilized CD8α. (c) Binding of WT CEACAM5 premixed with mAb B9 
(1:2) to immobilized CD8α peptide. 
 
2.5 DISCUSSION 
Our previous studies have focused on a novel role for IECs as antigen presenting 
cells. In the normal state, IECs acts as non professional antigen presenting cells, 
such presentation results in the selective activation of CD8+ suppressor T cells. 
We have characterized this interaction by identifying two molecules expressed by 
normal IECs which bind to the T cell receptor (TCR) and CD8 molecules on 
these regulatory T cells, CD1d and gp180, respectively. We have also generated 
a monoclonal antibody that specifically recognizes gp180. We have determined 
that this mAb was epithelial cell specific; it inhibited IEC induced CD8+ T cell 
proliferation and blocked the activation of CD8-associated Lck. This approach 
has lead to the identification of molecules involved in IEC:T cell interactions, 
specifically CD8+ T cells. Purified gp180 was shown to be important in activating 
Lck through binding to CD8α and CD1d (8-18). 
All CEACAms members have been shown to function, at least in vitro, as 
homotypic and heterotypic intercellular adhesion molecules. Modification in the 
expression of two GPI-anchored members, CEACAM5 and CEACAM6 have 
been shown to inhibit differentiation and anoikis, to disrupt cell polarization and 
tissue architecture, effects that altogether enhance tumorigenesis.  CEACAM1 
has been described to participate in the modulation of T cell function to bile acid 
transport (19-29). More recently, CEACAM6 has been proposed as a receptor for 
the type 1 pili expressed by adherent-invasive Escherichia coli (AIEC) and its 
abnormal expression seen in Crohn’s disease patients has been correlated to 
higher colonization and inflammation induced by AIEC (32). 
In this study we described homology between gp180 and CEACAM5. We 
showed that CEACAM5 has properties of gp180 such as binding to CD8α and 
induces Lck phosphorylation and interaction with CD1d. We confirmed that 
CEACAM5 interacts with CD1d through the B3-domain and that the sugar bridge 
between residues 70 and 81, which is the first highly conserved glycosylation site 
within the N-domain implicated in protein-protein interactions, is crucial for 
CEACAM5/CD8 binding and CD8 kinase Lck activation (26). Biacore protein-
protein affinity analysis validated that the N70,81A mutant strongly impacts 
CEACAM5/CD8 binding. Therefore glycosylation of the N-domain of CEACAM5 
is crucial for its interactions to CD8α. Moreover, we have proven that B9 mAb 
and CD8α have affinity to a similar binding site on CEACAM5 by competition 
experiments. These findings corroborate with previous observations and 
confirmed that B9 mAb blocks the induction of CD8+ regulatory T cells (Figure 9). 
We previously described that IECs derived from IBD patients have a defect in the 
expression of CEACAM5 (gp180) due to an evident failure to activate CD8+ 
regulatory T cells (33). Understanding the interactions between CEACAM5/CD1d 
and CD8α/TCR in the mucosal immune system in normal individuals will allow 
the development of new approaches to promote induction of suppressive 
immune responses (in Crohn’s disease) or to enhance mucosal immunity (oral 
vaccines). 
 
Figure 10. Interactions between CEACAM5/CD1d and CEACAM5/CD8α 
Intestinal epithelial cells express CEACAM5 and CD1d on their surface. 
CEACAM5 (gp180) interacts with CD1d through the B3 domain. Fragment 1 of 
the B3 domain is not required for its interaction with CEACAM5. The sugar bridge 
in the N domain of CEACAM5 is crucial for its binding to CD8α and for the 
activation of CD8-associated LcK (2).  
3. Overlapping peptide library as a tool for the development of synthetic  
          peptides to use as potential therapeutic agents. 
 
 
3.1 Background 
An overlapping peptide library is most commonly used for linear, continuous 
epitope mapping, where the aim is to generate a library of overlapping peptide 
sequences of specific length and specific offset, to cover a fragment or the entire 
native protein sequence. Characterized by two parameters, fragment length and 
offset number, each library is generated by breaking the original protein or 
peptide into many equal-length overlapping fragments, each has 8 to 20 
residues. The offset number is the number of amino acid residues shifted 
between adjacent fragments and it reflects the degree of overlap. The offset 
number is usually chosen to be 1/3 of the fragment length. We generated a 
specific overlapping peptide library of the N domain of CEACAM5 to figure out 
which part contains the essential amino acids that contribute to its functionality. 
 
                             
 
 
3.2 METHODS 
 
3.2.1 CEACAM5 overlapping peptide library 
The N domain of CEACAM5 consists in 108 aminoacid residues. We generated a 
peptides library of 20 peptides each of 15 mer with an offset of 5. (JPT, 
Innovative Peptides Solutions, Germany). 
 
 
Peptide no SEQUENCE 
1 H-KLTIESTPFNVAEGK-OH 
2 H-STPFNVAEGKEVLLL-OH 
3 H-VAEGKEVLLLVHNLP-OH 
4 H-EVLLLVHNLPQHLFG-OH 
5 H-VHNLPQHLFGYSWYK-OH 
6 H-QHLFGYSWYKGERVD-OH 
7 H-YSWYKGERVDGNRQI-OH 
8 H-GERVDGNRQIIGYVI-OH 
9 H-GNRQIIGYVIGTQQA-OH 
10 H-IGYVIGTQQATPGPA-OH 
11 H-GTQQATPGPAYSGRE-OH 
12 H-TPGPAYSGREIIYPN-OH 
13 H-YSGREIIYPNASLLI-OH 
14 H-IIYPNASLLIQNIIQ-OH 
15 H-ASLLIQNIIQNDTGF-OH 
16 H-QNIIQNDTGFYTLHV-OH 
17 H-NDTGFYTLHVIKSDL-OH 
18 H-YTLHVIKSDLVNEEA-OH 
19 H-IKSDLVNEEATGQFR-OH 
20 H-SDLVNEEATGQFRVY-OH 
 
Table 3: CEACAM5’s peptides library 
 
 
 
 
 
3.2.2 Isolation of human CD8+ T cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized 
venous blood on a Ficoll-Hypaque density gradient (Amersham Biosciences, 
Piscataway, NJ) according to standard procedures. PB CD8+ T cells were 
isolated by negative selection using a human CD8+ T-cell Enrichment Kit 
(StemCell Technologies Inc, Vancouver, British Colombia, Canada).  
 
3.2.3 In-Cell Western Blot 
In order to assess the functionality of CEACAM5 N domain peptides library we 
used The In-Cell Western™ Assay that is an immunocytochemical assay that 
uses NIR fluorescence to detect and quantify proteins in fixed cells.  
We selected 2 cells type to work with: 3G8 cell line and human isolated CD8+ T 
cells. Because the number of CD8+ T cells isolated from PBMC (peripheral blood 
monocular cells) is around 20% of total PBMC, the choice of this technique 
reduce the amount of cells needed for each condition. 
200 X 104 3G8 or CD8+ T cells were seeded in a 96 flat wells plate and starved 
in RPMI serum free medium overnight at 37oC. 
The day of the experiment the 96 plate was placed in ice for 15 minutes prior to 
perform the experiments. 
We performed a series of experiments where cells were stimulated with OKT8 
(10ug/mL) prior incubation with a IgG crosslinker for 15’, cross linker alone, 
H2O2 as positive control (0.8uM), purified CEACAM5 peptide (10 ug/mL), 
N70,81A CEACAM5 purified mutant, pool of peptides or different combination of 
petides for different time points (0, 2, 5, 10, 15 minutes). Unstimulated cells were 
obtained from each condition. A tritation assay was performed with 1, 10, 100 
ug/ml of the pool of peptides to assess the optimal concentration of peptides to 
use to perform all the experiments. 
Stimulation was stopped using a 4% formaldehyde buffer for 20 minutes followed 
by centrifugation for 10 minute at 15000 rpm. Permeabilization was performed 
washing Cells with 1x PBS containing 0.1% Triton x-100 for 5 minutes per wash. 
After permeabilization cells were incubated for 1 hour with the blocking buffer 
(Odyssey Blocking buffer-LICOR) and then the primaries antibodies goat anti-
actin and rabbit anti pLcK were added overnight at 4oC. The day after cells were 
washed 5 times with 1x PBS+0.1% Tweet 20 and incubated for 1 hour with the 
secondary antibodies (IRDye 800CW donkey anti goat IgG, IRDye 680 CW   
donkey anti rabbit IgG) for 1 hour at room temperature. Followed by 5 washes. 
Wells were dried and the plate was scanned using an Odyssey system. The 
software ImageStudio was used for quantification based on actin and 
background controls. 
 
 
 
3. Peptides functionality evaluation: CD8-associated LcK phosphorylation 
 
The tritation assay revealed that 10 ug/mL of peptide is the concentration that 
mimic the kinetic of the purified CEACAM peptide.  
The combination of 20 peptides that cover the entire N domain was capable of 
phosphorylated LcK in both 3G8 and human CD8+T cells at the same level as 
CEACAM5. 
We then grouped the peptides in 3 different pool:  
Pool1 to cover the aminoacid residues from 1 to 29,  
Pool2 to cover the aminoacid residues from 30 to 66 and 
Pool3 to cover the remaining aminoacids residues. 
This order was determined in agreement with the previous data that have shown 
that the aa residues 70 and 81 are crucial for CEACAM5 functionality.  
As expected, Pool 3 resulted in phosphorylation of LcK at a level comparable 
with the entire collection of peptides. On the contrary Pool 1 didn’t give any 
results. 
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Figure 11: Tritation assay: 10ug/mL of the entire collection of peptides 
determines phosphorylation of Lck at a level comparable to OKT8. 
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Figure 12: Phosphorylation of LcK in human isolated CD8+ T cells. A. 
Representation of 1 of 3 In-cell Western Blot experiments where Human CD8+ T 
cells were cultured in presence of OKT8+/-cross linker and presence of H2O2 
(positive control). B. Left panel: CEACAM5 purified peptide induces 
phosphorylation of LcK as well as the entire collection of peptides. The N70, 81A 
purified peptide induce phosphorylation at 2’ but the signal drop to the 
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Figure 13: Phosphorylation of LcK in 3G8 cell line. Left panel:  
Representation of 1 of 3 In-cell Western Blot experiments where 3G8 were 
cultured in presence of OKT8+ coated on the plate overnight and presence of 
H2O2 (positive control). Right panel:  The entire collection of peptides induce 
phosphorylation of Lck; Pool 3 determines phosphorylation in 2’ at a level 
comparable with OKT8.  
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3.4 Conclusion 
The CEACAM5 overlapping peptides library represents a tool to ascertain the 
epitope involved in CEACAM5 functionality. We have shown that we can create a 
collection of peptides without loosing the capability of CEACAM5 to 
phosphorylate CD8-associated LcK.  
Moreover we have already shown that the region where the residue N70 and 
N80 are located is crucial for CEACAM5 immunoregulatory function. 
More experiments are required to test each peptide individually. Moreover we 
plan to understand whether the role of CEACAM5 is the one of activation of CD8 
or it is a mechanism required for proliferation and differentiation. To address this 
question we will perform proliferation as well as suppression assay which will 
explain whether CEACAM5 is a trigger to induce a suppressive phenotype in 
normal homeostasis. Once, we will understand the whole role of CEACAM5 we 
will be able to use the peptides we generated in the development of new 
therapeutical strategy for the treatment of IBD. 
 
 
 
      
 
 
 
 
REFERENCES 
1. Bland, P.W. MHC class II expression by the gut epithelium. Immunol. 
Today 9, 174–178 (1988). 
2. Bland, P.W & Warren, L.G. Antigen presentation by epithelial cells of the 
rat small intestine. II. Selective induction of suppressor T cells. 
Immunology 58, 9–14 (1986). 
3. Bland, P.W. & Whiting, C.V. Antigen processing by isolated rat intestinal 
villus enterocytes. Immunology 68, 497–502 (1989).   
4. Hershberg, R. et al. Expression of the thymus leukemia antigen in mouse 
intestinal epithelium. Proc. Natl. Acad. Sci. 87, 9727–9731 (1990).  
5. Hershberg, R.M. et al. Intestinal epithelial cells use two distinct pathways 
for HLA class II antigen processing. J. Clin. Invest. 100, 204–215 (1997). 
6. Kaiserlian, D., Vidal, K. & Revillard, J.P. Murine enterocytes can present 
soluble antigen to specific class II restricted CD4+ T cells. Eur. J. 
Immunol. 19, 1513–1516 (1989). 
7. Mayer, L., So, L.P., Yio, X.Y. & Small, G. Antigen trafficking in the 
intestine. Ann. NY Acad. Sci. 778, 28–35 (1996). 
8. Yio, X.Y. & Mayer, L. Characterization of a 180-kDa intestinal epithelial 
cell membrane glycoprotein, gp180 A candidate molecule mediating t cell-
epithelial cell interactions. J Biol Chem 272, 12786–12792 (1997). 
9. Campbell, N.A. et al. A Non-class I MHC Intestinal Epithelial Surface 
Glycoprotein, gp180, Binds to CD8. Clinical Immunology 102, 267-274 
(2002). 
10. Allez, M., Brimnes, J., Dotan, I. & Mayer, L. Expansion of CD8+ T cells 
with regulatory function after interaction with intestinal epithelial cells. 
Gastroenterology 123:1516–1526 (2002).  
11. Allez, M., Brimnes, J., Shao, L., Dotan, I., Nakasawa, A. & Mayer, L.. 
Activation of a unique population of CD8(+) T cells by intestinal epithelial 
cells. Ann N Y Acad Sci. 1029, 22–35 (2004).  
12. Allez, M. & Mayer, L. Regulatory T cells: peace keepers in the gut. 
Inflamm Bowel Dis 10, 666–676 (2004).  
13. Arosa, F.A., Irwin, C., Mayer, L., de Sousa, M. & Posnett, D.N. 
Interactions between peripheral blood CD8 T lymphocytes and intestinal 
epithelial cells (IEC). Clin Exp Immunol 112, 226–236 (1998)_.  
14. Li, Y., Yio, X.Y. & Mayer, L. Human intestinal epithelial cell-induced CD8+ 
T cell activation is mediated through CD8 and the activation of CD8-
associated p56Lck. J Exp Med 182, 1079–1088 (1995).  
15. Mayer, L. IBD: immunologic research at The Mount Sinai Hospital. Mt 
Sinai J Med. 67, 208–213 (2000).  
16. Somnay-Wadgaonkar, K. et al. Immunolocalization of CD1d in human 
intestinal epithelial cells and identification of a beta2-microglobulin-
associated form. Int Immunol. 11, 383–392 (1999).  
17. Van de Wal, Y. et al. Delineation of a CD1d-restricted antigen presentation 
pathway associated with human and mouse intestinal epithelial cells. 
Gastroenterology 124 1420–1431 (2003). 
18. Toy, L.S., Yio, X.Y., Lin, A., Honing, S., Mayer, L. Defective expression of 
gp180, a novel. CD8 ligand on intestinal epithelial cells, in inflammatory 
bowel disease. J Clin Invest 100, 2062–2071(1997). 
19. Hammarström, S. The carcinoembryonic antigen (CEA) family: structures, 
suggested functions and expression in normal and malignant tissues. 
Semin Cancer Biol 9(2), 67-81 (1999).  
20. Kinugasa, T. et al. Expression of four CEA family antigens (CEA, NCA, 
BGP and CGM2) in normal and cancerous gastric epithelial cells: up-
regulation of BGP and CGM2 in carcinomas. Int J Cancer 30,76(1), 148-
53 (1998). 
21. Frangsmyr, L., Baranov, V. & Hammarstrom, S. Four carcinoembryonic 
antigen subfamily members, CEA, NCA, BGP and CGM2, selectively 
expressed in the normal human colonic epithelium, are integral 
components of the fuzzy coat. Tumour Biol 20, 277–292 (1999). 
22. Kuespert, K., Pils, S. & Hauck, C.R.  CEACAMs: their role in physiology 
and pathophysiology. Curr Opin Cell Biol 18(5), 565-71 (2006). 
23. Yan, Z. et al. Oncogenic c-Ki-ras but not oncogenic c-Ha-ras up-regulates 
CEA expression and disrupts basolateral polarity in colon epithelial cells. J 
Biol Chem 272, 27902–27907 (1997). 
24. Ordonez, C., Screaton, R.A., Ilantzis, C. & Stanners, C.P. Human 
carcinoembryonic antigen functions as a general inhibitor of anoikis. 
Cancer Res. 60, 3419–3424 (2000). 
25. Wirth, T., Soeth, E., Czubayko, F. & Juhl, H. Inhibition of endogenous 
carcinoembryonic in Crohn disease antigen (CEA) increases the apoptotic 
rate of colon cancer cells and inhibits metastatic tumor growth. Clin Exp 
Metastasis 19, 155–160 (2002). 
26. Bates PA, Luo J, Sternberg MJ. A predicted three-dimensional structure 
for the carcinoembryonic antigen (CEA). FEBS Lett. 1992;301(2):207-14. 
27. Gangopadhyay, A., Lazure, D.A. & Thomas, P. Adhesion of colorectal 
carcinoma cells to the endothelium is mediated by cytokines from CEA 
stimulated Kupffer cells. Clinical and Experimental Metastasis 8, 703-712 
(1998).  
28. Morales, V.M. et al. Regulation of human intestinal intraepithelial 
lymphocyte cytolytic function by biliary glycoprotein (CD66a). J Immunol 
163(3), 1363-70 (1999). 
29. Kammerer, R., Stober, D., Singer, B.B., Obrink, B. & Reimann, J. 
Carcinoembryonic antigen-related cell adhesion molecule 1 on murine 
dendritic cells is a potent regulator of T cell stimulation. J. Immunol 166, 
6537-44 (2001).  
30. Huang, J., Lindsay, J., Evavold, B.D. & Cheng, Z. Kinetic of the MHC-CD8 
interaction at the T cell membrane. J Immunol 179, 7653-7662 (2007). 
31. Jelonek, M.T., Classon, B.J., Hudson, P.J. & Margulies, D.H. Direct 
Binding of the MHC Class I Molecule H-2Ld to CD8: Interaction with the 
Amino Terminus of a Mature Cell Surface Protein. The Journal of 
Immunology 160, 2809-2814 (1998). 
32. Barnich, N. & Darfeuille-Michaud, A. Abnormal CEACAM6 expression 
patients favors gut colonization and inflammation by adherent-invasive E. 
coli. Virulence 1(4), 281-2 (2010). 
33. Roda, G. et al. Defect in CEACAM Family Member Expression in Crohn’s 
Disease IECs Is Regulated by the Transcription Factor SOX9. Inflamm 
Bowel Dis 15(12), 1775-83 (2009). 
 
 
 
 
 
 
 
 
